Eyenovia, Inc. announced that the FDA has approved Eyenovia?s Supplemental New Drug Application (sNDA), adding Coastline International as a contract manufacturer. Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis (office-based pupil dilation).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7713 USD | -4.14% | -23.63% | -62.92% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.92% | 39.3M | |
+30.38% | 684B | |
+29.32% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.35% | 240B | |
+8.74% | 208B | |
-7.81% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- EYEN Stock
- News Eyenovia, Inc.
- Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production